This study shows that in severe influenza, TLR7 antagonist treatment ameliorates both type I interferon–driven and interferon-independent immunopathology by blocking TLR7-dependent cytokine production by immune cells, without affecting RIG-I–dependent responses in lung epithelia. The gene discussed is RIGI; the disease is influenza.